When pERK levels were monitored in 2 KRASG12C cell lines [SW1463 (KRASG12C/G12C, colorectal cancer) and NCI-H2030 (KRASG12C/G12C, NSCLC)] up to 72 hours, KRASG12C mutant-selective inhibitor adagrasib treatment resulted in significant rebound of pERK signal over the course of 24 to 72 hours (Supplementary Fig. S1E). Here, EIF2AK3 is linked to non-small cell lung carcinoma.